110 related articles for article (PubMed ID: 22628061)
1. Propanolol and angiogenesis inhibition in hereditary haemorrhagic telangiectasia.
Breier G
Thromb Haemost; 2012 Jul; 108(1):1-2. PubMed ID: 22628061
[No Abstract] [Full Text] [Related]
2. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia.
Albiñana V; Recio-Poveda L; Zarrabeitia R; Bernabéu C; Botella LM
Thromb Haemost; 2012 Jul; 108(1):41-53. PubMed ID: 22552254
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: retrospective, then prospective study, in a total of 21 patients.
Contis A; Gensous N; Viallard JF; Goizet C; Léauté-Labrèze C; Duffau P
Clin Otolaryngol; 2017 Aug; 42(4):911-917. PubMed ID: 28032956
[No Abstract] [Full Text] [Related]
4. Angiogenesis-dependent diseases and angiogenesis therapy.
Tímár J; Döme B; Fazekas K; Janovics A; Paku S
Pathol Oncol Res; 2001; 7(2):85-94. PubMed ID: 11458270
[TBL] [Abstract][Full Text] [Related]
5. Re-treating bleeding hereditary haemorrhagic telangiectasia with bevacizumab.
Ho GY; Zhong E; Chern B
Med J Aust; 2013 Nov; 199(10):658. PubMed ID: 24237088
[No Abstract] [Full Text] [Related]
6. Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia.
Suppressa P; Liso A; Sabbà C
Br J Haematol; 2011 Feb; 152(4):365. PubMed ID: 21265821
[No Abstract] [Full Text] [Related]
7. Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.
Pan WK; Li P; Guo ZT; Huang Q; Gao Y
Pediatr Blood Cancer; 2015 Aug; 62(8):1414-20. PubMed ID: 25728347
[TBL] [Abstract][Full Text] [Related]
8. More on bevacizumab in hereditary hemorrhagic telangiectasia.
Retornaz F; Rinaldi Y; Duvoux C
N Engl J Med; 2009 Aug; 361(9):931; author reply 931-2. PubMed ID: 19714790
[No Abstract] [Full Text] [Related]
9. More on bevacizumab in hereditary hemorrhagic telangiectasia.
Oosting S; Nagengast W; de Vries E
N Engl J Med; 2009 Aug; 361(9):931; author reply 931-2. PubMed ID: 19710496
[No Abstract] [Full Text] [Related]
10. Is bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia?
Chin CJ
Laryngoscope; 2017 Feb; 127(2):289-290. PubMed ID: 27796042
[No Abstract] [Full Text] [Related]
11. Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: a word of caution.
Buscarini E; Manfredi G; Zambelli A
Liver Transpl; 2008 Nov; 14(11):1685-6; author reply 1687-8. PubMed ID: 18975280
[No Abstract] [Full Text] [Related]
12. Long-term therapy with thalidomide in hereditary hemorrhagic telangiectasia: case report and literature review.
Chen CH; Hsu HH; Hu RH; Lee PH; Ho CM
J Clin Pharmacol; 2012 Sep; 52(9):1436-40. PubMed ID: 22031620
[No Abstract] [Full Text] [Related]
13. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion.
Annabi B; Lachambre MP; Plouffe K; Moumdjian R; Béliveau R
Pharmacol Res; 2009 Nov; 60(5):438-45. PubMed ID: 19467330
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide.
Lacout A; Marcy PY; El Hajjam M; Lacombe P
Med Hypotheses; 2013 May; 80(5):587-8. PubMed ID: 23452644
[TBL] [Abstract][Full Text] [Related]
15. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia.
Brinkerhoff BT; Poetker DM; Choong NW
N Engl J Med; 2011 Feb; 364(7):688-9. PubMed ID: 21323562
[No Abstract] [Full Text] [Related]
16. Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia.
Young LH; Henderson KJ; White RI; Garcia-Tsao G
Hepatology; 2013 Jul; 58(1):442-5. PubMed ID: 23686865
[No Abstract] [Full Text] [Related]
17. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.
Ospina FE; Echeverri A; Posso-Osorio I; Jaimes L; Gutierrez J; Tobón GJ
Colomb Med (Cali); 2017 Jun; 48(2):88-93. PubMed ID: 29021642
[TBL] [Abstract][Full Text] [Related]
18. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and hereditary haemorrhagic telangiectasia.
Cruikshank RP; Chern BW
Med J Aust; 2011 Mar; 194(6):324-5. PubMed ID: 21426291
[No Abstract] [Full Text] [Related]
20. [Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].
Holz FG; Heeren TF; Krüger E; Zeimer M; Pauleikhoff D; Charbel Issa P
Ophthalmologe; 2014 Sep; 111(9):834-8. PubMed ID: 25204529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
